Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim accurately reflects the label’s boxed warning/Section 5.1 about increased suicidality risk in children, adolescents, and young adults and the label’s instruction for close monitoring, including when initiating therapy or adjusting doses.
Category Scores
Accurate Statements
PROZAC (fluoxetine) has a warning about increased risk of suicidal thoughts and behaviors (suicidality), particularly in children, adolescents, and young adults.
Box Warning; 5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
The warning requires close monitoring.
5.1 includes instruction to monitor appropriately and observe closely for clinical worsening and suicidality; Box Warning includes monitoring guidance; 17 includes caregiver/family alerting and day-to-day observation
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention the label’s age-specific nuances (no increased risk beyond age 24; reduced risk in adults ≥65) or the specific monitoring timing (especially during the initial few months and at dose changes).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim aligns with labeled boxed warning content and monitoring requirements; omissions are limited to additional label details rather than safety-reversing or contradictory information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not include certain label-specific qualifiers (age 24+ nuance and initial months/dose-change timing).
Suggested Improvement
Optionally add that risk pertains to children/adolescents/young adults and that patients should be monitored closely especially during the initial months of therapy and during dose changes, consistent with Section 5.1.